Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...

Key opportunities in the prostate cancer market include innovation in androgen receptor degraders, radiopharmaceuticals, and immune-targeted therapies. Strategic collaborations and acquisitions ...

Maurice Blake says he never knew that one-in-four black men face prostate cancer - double the average.

Telix shares surge as much as 14% after its most advanced cancer therapy candidate passes phase III safety and dosimetry hurdles Clarity says it will achieve the targeted 220 patients for its prostate ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing partner, Accord Healthcare, that the European Medicines Agency's (EMA) Committee for ...